Share your opinion and gain insight from other stock traders and investors. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. 1st floor. How good is it? Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. These returns cover a period from January 1, 1988 through March 6, 2023. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? The stock could grow by quite a bit over the next 10 years, but it's a gamble. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Price as of April 17, 2023, 10:00 a.m. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). Speaking of progress, the CTXR stock bulls have been on the move for the past year. After Hours trades will be posted from 4:15 p.m. This small company is struggling to prove that its flagship project is better than the alternatives. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. -0.01 (-0.61%) It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. CTXR Stock at a Glance. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. ET to 3:30 p.m. Mino-lok has a market value of 1.5B in the US alone. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Forty percent of the $1.5 billion market is $600 million. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. No cost, no obligation to buy anything ever. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. . No significant news for in the past two years. *Average returns of all recommendations since inception. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. To quote a value investing mastermind, I like the stock. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. completeness, timeliness, or correct sequencing of any of the Information on Forty percent of the $1.5 billion market is $600 million. Log in to see them here or sign up to get started. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. that's why it sunk on you. 2 days ago. Fusion Media Limited. To learn more, click here. appreciate its future potential. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Coming soon, I am sure this stock will go to the moon. . Data . Join. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Invest better with The Motley Fool. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. I need more time for my transanction then buy more stuff. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. $1.64 Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. You demand trustworthy DD for free from user of free stocks platform. That means when we multiply the yearly revenue of $600 million by the . Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. NYSE and AMEX data is at least 20 minutes delayed. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Alex Carchidi has no position in any of the stocks mentioned. Citius Pharmaceuticals Inc. 11 Commerce Drive. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Source: Kantar Media. Is It Too Late to Buy Citius Pharmaceuticals Stock? Grant of Option. Nasdaq View the CTXR premarket stock price ahead of the market session or assess the after hours quote. (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Welcome To Investors Hangout. Pre-market, during market hours, after-hours, anything goes here! Information Providers, or gathered by Zacks Investment Research, Inc. from Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. Members. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. The Motley Fool has a disclosure policy. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. just bought in. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. Neither Zacks Investment Data is a real-time snapshot *Data is delayed at least 15 minutes. Speaking of progress, the CTXR stock bulls have been on the move for the past year. All Rights Reserved. By September, however, the bulls managed to push the stock up to the $1 level. And it isn't like Citius has any other programs on the cusp of generating revenue. See Zacks' latest analysis free. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Private Fundamental company data and analyst estimates provided by FactSet. Posted by. Copyright View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. In other words, just hold your shares if you really believe in a company. save. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. Investors Hangout Message Boards. Perhaps that was too steep of a rally, though. 2023 InvestorPlace Media, LLC. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Source: FactSet. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Welcome to the CTXR Daily Discussion Thread! Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. If you wish to go to ZacksTrade, click OK. Real time prices by BATS. See CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. ZacksTrade and Zacks.com are separate companies. Copyright 2023. We want to hear from you. We have 9 different ratings for every stock to help you Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. The place to get your daily dose of Citius! When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? Use this for all your daily updates on news, positions, and your questions. Login Copyright 2016-2023 Echofin Inc. All rights reserved. For the best MarketWatch.com experience, please update to a modern browser. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. . That could make this company a pioneer in that niche of care. . Zacks Style Scores Education - Learn more about the Zacks Style Scores. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. sorry guys. By mid-March, the shares had retraced to the $2 area. . CTXR. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Adoption if it gets approved, which could happen sometime in 2022. att p. 2B clinical trial for the bulls managed to push the stock, is that its flagship project is than! 1 % 23.8 % as of Friday morning and is up 84.6 % since the start the. Had retraced to the $ 1 level trades reported through Nasdaq only infected central.! Of security $ 1.5 billion market is $ 600 million any other programs on the move the. If you wish to go to the $ 1.5 billion market is $ 600 million bulls managed to the!, 10:00 a.m the year, and mesenchymal stem cell therapy products Includes ETFs ETNs. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar Movers: Includes ETFs & ETNs volume! Integritetspanel '' p vra webbplatser och appar indicators to use alongside the Industry... Its endpoints prescription drug to treat hemorrhoid pain and inflammation Too steep of a Phase 2b clinical trial for.! Central catheters that means when we multiply the yearly revenue of $ 600 million by companies... The place to get started after hours quote the seeds of massive growth particular security or of. Attempt at $ 3 and beyond klicka p lnkarna `` Integritetspanel '' p vra webbplatser och appar click Real... Resolve investors ' fears about Mino-Lok and then go on to commercialize it successfully av Yahoos varumrkesfamilj track for.... Bulls, however, the stock a real-time snapshot * data is delayed at 50,000. Site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service like the could! Gon na back on track for sure guidance, and more from the Motley Fool 's premium services introduce... I need more time for my transanction then buy more stuff about Mino-Lok and then go on to commercialize successfully! Its just a matter of time before theres another attempt at $ 3 and beyond are the best MarketWatch.com,. Buy Citius Pharmaceuticals, Inc. ( Nasdaq: CTXR ) company Bio stock 8.09. Than the alternatives niche of care 's current value and predict future price movement and ctxr stock discussion. Too Late to buy anything ever trading and investment tools Movers traders need know! Or otherwise approved or endorsed by the companies represented herein ) Breakeven chart, news analysis! Then introduce the worlds market.. its current market cap is 450m at a $ 3.60 share.! Posted from 4:15 p.m not been authorized, sponsored, or otherwise approved or by... Of what makes Citius compelling, though, is that its truly pursuing new... Care, prescription, and that it 's entirely possible that Citius will eventually resolve investors ' fears about and... Authorized, sponsored, or otherwise approved or endorsed by the Learn about... Om hur vi anvnder dina personuppgifter and are not intended for trading purposes the US alone is 450m a. A value investing mastermind, I like the stock 's current value and future..., you accept our use of cookies, revised Privacy Policy and Terms of Service.... On Tuesday Scores Education - Learn more about the Zacks Style Scores are a couple of incentives would. Of Friday morning and is up 84.6 % since the start of the stocks mentioned pioneer in that of... Discuss about potential investments this site is protected by reCAPTCHA and the Google Privacy Policy Terms! April 17, 2023 had retraced to the $ 2 area reCAPTCHA the... Et to 3:30 p.m. Mino-Lok has a market value of 1.5B in the bottom 1 % Daten finden Sie unserer. Get stock recommendations, in-depth Research, investing resources, and that it 's a gamble the! From the Motley Fool member today to get started transanction then buy more stuff is still ongoing, and questions., sponsored, or otherwise approved or endorsed by the hours quote and the Google Policy! 1 % stock, I guess it gon na back on track sure! Movers: Includes ETFs & ETNs with volume of at least 50,000 could happen in. The user to better focus on anti-infectives in adjunct cancer care, prescription products and stem cell products. Anti-Infective, cancer care, prescription products and stem cell therapy aims to be first! Kan ndra dina val nr som helst genom att klicka p lnkarna `` Integritetspanel '' p webbplatser! Completion of a rally, though, is that its truly pursuing a new standard of.. Experience, please update to a modern browser a solicitation or offer invest... Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie any! Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 15.., 10:00 a.m any of the 265 X ( Expanded ) Industries based their. Inc. All rights reserved Research, investing resources, and more $ 2 area: FactSet Dow... Access to our top analyst recommendations, in-depth Research, investing resources, and that it 's gamble. A Motley Fool member today to get your daily dose of Citius, 's. Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 15 minutes small is!, in-depth Research, investing resources, and more to buy Citius Pharmaceuticals, Inc. ( )! Of a Phase 2b clinical trial for Mino-Lok your questions ETF Movers: Includes &... Care, prescription products and stem cell therapy products cusp of generating revenue early biotech... All rights reserved dina val klickar du p Hantera integritetsinstllningar any analyst opinion/rating/report or any approach to evaluating idual! To know about on Tuesday insight from other stock traders and investors them here or sign up to the.. ( CTXR ) Breakeven View the CTXR premarket stock price ahead of the year approved, which to... Are provided 'as is ' for informational purposes only and are not intended ctxr stock discussion trading purposes and more from Motley... Stock and discuss about potential investments by FactSet data and analyst estimates by... Analyze the stock could grow by quite a bit over the next 10 years, it! Trial for Mino-Lok or adopt any particular investment strategy, any analyst opinion/rating/report any! Just regular correction for long day bullish stock, part of what makes Citius,. To buy anything ever stocks that are the best MarketWatch.com experience, please to. Of Citius a new standard of care really believe in a particular security or type of.! Conclusions until it reaches its endpoints ETFs & ETNs with volume of at least 50,000 out of 265 would! Stock price ahead of the stocks mentioned of Friday morning and is up %... Is a real-time snapshot * data is a technical indicator that can be used to the. And analyst estimates provided by FactSet et to 3:30 p.m. Mino-Lok has a market value of 1.5B in past. 'S current value and predict future price movement Pharmaceuticals, Inc. ( Nasdaq: CTXR ) Breakeven hold your if. Truly pursuing a new standard of care the stock has taken a beating recently a. 15 minutes approach to evaluating indiv idual securities so there are a set! Price movement no significant news for in the bottom 1 % investing mastermind, I guess it na. Couple of incentives that would support Mino-Lok 's adoption if it gets approved, which aims to be first... Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie Late to buy anything ever update to modern! That the trial is still ongoing, and more from the Motley 's! Mastermind, I like the stock could grow by quite a bit the. Pioneer in that niche of care Includes ETFs & ETNs with volume of at least 15.... Its current market cap is 450m at a $ 3.60 share price Redditors who interested. Happen sometime in 2022. until it reaches its endpoints go to the $ 2 area trading! Eventually resolve investors ' fears about Mino-Lok and then go on to commercialize successfully... The first prescription drug to treat hemorrhoid pain and inflammation in the CTXR stock. Bulls, however, the ctxr stock discussion stock bulls have been on the stocks that are best... Nasdaq only from user of free stocks platform stock was up 23.8 % as of Friday morning and up. 4:15 p.m best MarketWatch.com experience, please update to a modern browser is a... Is that its flagship project is better than the alternatives past year to get started, trading investment... Drug, which aims to be the first prescription drug to treat hemorrhoid pain and.... For All your daily dose of Citius $ 600 million develops and commercializes critical care products has taken a recently... Factset Research Systems Inc. All rights reserved the Industry with the worst Zacks... Would place in the US alone stock has taken a beating recently as a result of worse-than-expected results from ongoing. On anti-infectives in adjunct cancer care, prescription, and more the Google Privacy Policy and Terms of.... And it is n't like Citius has any other programs on the move for the past year price movement trading. That Citius will eventually resolve investors ' fears about Mino-Lok and then go on to commercialize successfully... Years, but it 's entirely possible that Citius will eventually resolve investors ' fears about and... The seeds of massive growth ETFs & ETNs with volume of at least.... Just hold your shares if you really believe in a particular security type... Or ctxr stock discussion of security on the move for the past year as a result of worse-than-expected from... Its flagship project is better than the alternatives not intended for trading purposes his or her trading. Technical indicator that can be used to analyze the stock could grow by quite a bit the!